HK1257555A1 - Tec激酶家族之抑制劑 - Google Patents
Tec激酶家族之抑制劑Info
- Publication number
- HK1257555A1 HK1257555A1 HK18116516.1A HK18116516A HK1257555A1 HK 1257555 A1 HK1257555 A1 HK 1257555A1 HK 18116516 A HK18116516 A HK 18116516A HK 1257555 A1 HK1257555 A1 HK 1257555A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitors
- kinase enzyme
- enzyme family
- tec kinase
- tec
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2892548 | 2015-05-27 | ||
CA2906760 | 2015-09-29 | ||
PCT/CA2016/050606 WO2016187723A1 (en) | 2015-05-27 | 2016-05-27 | Inhibitors of the tec kinase enzyme family |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1257555A1 true HK1257555A1 (zh) | 2019-10-25 |
Family
ID=57393271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18116516.1A HK1257555A1 (zh) | 2015-05-27 | 2018-12-24 | Tec激酶家族之抑制劑 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180179210A1 (zh) |
EP (1) | EP3337805A4 (zh) |
CA (1) | CA3025813A1 (zh) |
HK (1) | HK1257555A1 (zh) |
WO (1) | WO2016187723A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018156901A1 (en) * | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
EP3886854A4 (en) | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
WO2021011428A1 (en) * | 2019-07-12 | 2021-01-21 | Gb005, Inc. | Heterocyclic kinase inhibitors |
WO2021125313A1 (ja) * | 2019-12-19 | 2021-06-24 | 大鵬薬品工業株式会社 | 縮合ピリミジン化合物を有効成分とする治療剤 |
CN112608243A (zh) * | 2020-12-15 | 2021-04-06 | 深圳市华先医药科技有限公司 | 一种反式-3-氨基丁醇的合成方法 |
CN117279910A (zh) | 2021-04-16 | 2023-12-22 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2855484A4 (en) * | 2012-05-31 | 2015-12-16 | Pharmascience Inc | PROTEIN KINASE INHIBITORS |
CA2813299A1 (en) * | 2013-04-17 | 2014-10-17 | Pharmascience Inc. | Protein kinase inhibitors |
CA2779184A1 (en) * | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Protein kinase inhibitors |
CA2782774A1 (en) * | 2012-07-06 | 2014-01-06 | Pharmascience Inc. | Protein kinase inhibitors |
CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
CA2833867A1 (en) * | 2013-11-21 | 2015-05-21 | Pharmascience Inc. | Protein kinase inhibitors |
CA2834528A1 (en) * | 2013-11-26 | 2015-05-26 | Pharmascience Inc. | Protein kinase inhibitors |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2016
- 2016-05-27 WO PCT/CA2016/050606 patent/WO2016187723A1/en active Application Filing
- 2016-05-27 US US15/577,136 patent/US20180179210A1/en not_active Abandoned
- 2016-05-27 EP EP16799005.0A patent/EP3337805A4/en not_active Withdrawn
- 2016-05-27 CA CA3025813A patent/CA3025813A1/en not_active Abandoned
-
2018
- 2018-12-24 HK HK18116516.1A patent/HK1257555A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3337805A1 (en) | 2018-06-27 |
EP3337805A4 (en) | 2019-04-03 |
US20180179210A1 (en) | 2018-06-28 |
WO2016187723A1 (en) | 2016-12-01 |
CA3025813A1 (en) | 2016-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283267B (en) | Inhibitors of menin–mll interaction | |
IL267215A (en) | Imidazopyrrolopyridines as inhibitors of the jak family of kinases | |
IL259560A (en) | Inhibitors of the menin-mll interaction | |
PL3512850T3 (pl) | Inhibitory interakcji menina-mll | |
EP3247692A4 (en) | INHIBITORS OF TRKA KINASE | |
IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
EP3177295A4 (en) | Uses of salt-inducible kinase (sik) inhibitors | |
PL3166608T3 (pl) | Związki aminopirydazynonowe jako inhibitory kinaz białkowych | |
EP3149008B8 (en) | Certain protein kinase inhibitors | |
HK1257555A1 (zh) | Tec激酶家族之抑制劑 | |
IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
EP3288931A4 (en) | Certain protein kinase inhibitor | |
EP3186247A4 (en) | Protein kinase inhibitors | |
ZA201808238B (en) | Certain protein kinase inhibitors | |
EP3224248A4 (en) | Certain protein kinase inhibitors | |
IL247025A0 (en) | enzyme inhibitors | |
EP3347357A4 (en) | HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY | |
AU2016904206A0 (en) | Novel kinase inhibitors i | |
GB201609517D0 (en) | Enzyme inhibitors | |
GB201614783D0 (en) | Kinases inhibitors | |
AU2015904223A0 (en) | Novel kinase inhibitors i | |
AU2015903106A0 (en) | Novel kinase inhibitors ii | |
GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors |